Could a liver artery shot make cancer treatment more effective?
NCT ID NCT04544098
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether giving the drug Lutathera directly into the liver artery is safe and practical for people with neuroendocrine tumors that have spread mainly to the liver. Ten participants will receive two doses into the liver artery followed by two standard IV doses. Researchers will compare the two methods and check if the tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutathera (177Lu-DOTATATE)
What this could lead to
If this works, it could show a new way to deliver Lutathera that is more effective for liver tumors, potentially improving control of neuroendocrine cancer that has spread to the liver.
What could go wrong
This is a very early, small pilot study with only 10 people, so results may not apply widely. The treatment involves radiation and may cause side effects like liver damage or low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States